Finding ways to reduce side effects from prostate cancer radiation treatment using genetics.
Reducing toxicity from prostate cancer radiotherapy through genetics and technology
['FUNDING_R37'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-10945982
This study is looking at how certain genes might help doctors figure out which men with localized prostate cancer could have tough side effects from radiation therapy, so they can tailor treatments to make things easier for them.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10945982 on ClinicalTrials.gov |
What this research studies
This research aims to identify genetic markers that can help predict which prostate cancer patients are likely to experience severe side effects from radiation therapy. By analyzing specific genetic variations, known as single nucleotide polymorphisms (SNPs), the study seeks to personalize treatment plans and minimize adverse effects. The approach involves collecting genetic data from patients and correlating it with their responses to radiation therapy, ultimately improving patient quality of life. This research is particularly focused on localized prostate cancer, a common condition treated with radiation.
Who could benefit from this research
Good fit: Ideal candidates for this research are prostate cancer patients undergoing radiation therapy who are interested in understanding their genetic predisposition to treatment-related side effects.
Not a fit: Patients who are not undergoing radiation therapy for prostate cancer or those with advanced metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized radiation treatments that reduce harmful side effects for prostate cancer patients.
How similar studies have performed: Previous research has shown promise in identifying genetic markers for treatment toxicity in other cancers, suggesting that this approach may yield valuable insights for prostate cancer as well.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KISHAN, AMAR U — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: KISHAN, AMAR U
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Radiation Syndrome, Cancer Cause, Cancer Etiology, Cancer Patient, Cancer Radiotherapy